Rapid assessment of avoidable blindness and diabetic retinopathy in Taif, Saudi Arabia.

BACKGROUND/AIMS: To estimate the prevalence of blindness, diabetes and diabetic retinopathy (DR) in Taif, Saudi Arabia using the Rapid Assessment of Avoidable Blindness (RAAB) framework. METHODS: 66 clusters of 50 people aged ≥50 years were randomly selected. Participants underwent visual acuity measurement and examination by an ophthalmologist. DR among diabetic participants (previous diagnosis and/or random blood glucose >200 mg/dl) was assessed through dilated fundus examination by an ophthalmologist using a direct and indirect ophthalmoscope ('clinical examination') and dilated digital fundus photographs graded by a retinal specialist following the Scottish DR grading system ('reference standard'). RESULTS: 3052 (93%) out of 3300 eligible people were examined. The prevalence of blindness was 2.6% (95% CI 2.0% to 3.2%). Posterior segment diseases (44%) and cataract (41%) were the leading causes of blindness. The estimated prevalence of diabetes was 29.7% (28.1% to 31.4%), among whom the prevalence of DR was 36.8% (33.3% to 40.2%) and sight-threatening DR (STDR) was 17.5% (CI 15.1% to 20.0%). Agreement was good (κ>0.6) between the clinical examination and reference standard for any DR and STDR. CONCLUSIONS: There was a high prevalence of diabetes, DR and STDR. It was possible to assess diabetes and DR within RAAB but it increased the survey duration, cost and complexity

Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study

OBJECTIVES: Paediatric cancer is a leading cause of death for children. Children in low-income and middle-income countries (LMICs) were four times more likely to die than children in high-income countries (HICs). This study aimed to test the hypothesis that the COVID-19 pandemic had affected the delivery of healthcare services worldwide, and exacerbated the disparity in paediatric cancer outcomes between LMICs and HICs. DESIGN: A multicentre, international, collaborative cohort study. SETTING: 91 hospitals and cancer centres in 39 countries providing cancer treatment to paediatric patients between March and December 2020. PARTICIPANTS: Patients were included if they were under the age of 18 years, and newly diagnosed with or undergoing active cancer treatment for Acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, Wilms' tumour, sarcoma, retinoblastoma, gliomas, medulloblastomas or neuroblastomas, in keeping with the WHO Global Initiative for Childhood Cancer. MAIN OUTCOME MEASURE: All-cause mortality at 30 days and 90 days. RESULTS: 1660 patients were recruited. 219 children had changes to their treatment due to the pandemic. Patients in LMICs were primarily affected (n=182/219, 83.1%). Relative to patients with paediatric cancer in HICs, patients with paediatric cancer in LMICs had 12.1 (95% CI 2.93 to 50.3) and 7.9 (95% CI 3.2 to 19.7) times the odds of death at 30 days and 90 days, respectively, after presentation during the COVID-19 pandemic (p<0.001). After adjusting for confounders, patients with paediatric cancer in LMICs had 15.6 (95% CI 3.7 to 65.8) times the odds of death at 30 days (p<0.001). CONCLUSIONS: The COVID-19 pandemic has affected paediatric oncology service provision. It has disproportionately affected patients in LMICs, highlighting and compounding existing disparities in healthcare systems globally that need addressing urgently. However, many patients with paediatric cancer continued to receive their normal standard of care. This speaks to the adaptability and resilience of healthcare systems and healthcare workers globally